Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Blueprint Medicines (BPMC) Misses Q4 EPS by 7c, Revenues Miss
February 26, 2019 7:22 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.83), $0.07 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.68 million.
"Following a year of remarkable clinical progress across our portfolio in 2018, we are focused on... More
